Important Information
If you are interested in applying for this study, please:
- Read the study description.
- Review the Visit Planner dates in your location and confirm that you are available for the stated dates.
- If you have not yet registered with us, click on the ‘Register’ button at the top of this page and answer the questions.
- If you have already registered with us, answer the pre-screening questions listed below and submit your interest.
We will then contact you to check your suitability and share the Participant Informed Consent Form for you to read.
Study Information
This study will test an investigational medication, named NEU-627, designed to treat Multiple Sclerosis (MS). MS is an inflammatory disease of the brain and spinal cord that is the most common cause of neurological disability in young adults. MS causes communication problems between the brain and the rest of the body, leading to various symptoms like fatigue, muscle weakness, and difficulty with coordination and balance. MS also causes changes in cognitive abilities such as impairments in memory, attention and processing speed. There are around 4,000 people in New Zealand diagnosed with MS. Currently there is no cure for MS, there are only medications with varying efficacy that are used to slow disease progression.
NEU-627 can enter the blood and the brain and works by inhibiting (stopping or blocking) TYK2. TYK2 is known to be important in regulating multiple inflammatory pathways. It is hoped that by regulating inflammation in the brain and spinal cord, it may be an effective treatment for MS.
This is an investigational medicine because it has not been approved by MedSafe or other drug regulatory authorities.
This study 2025 FULL 22600 is being funded by Neuron23 Inc., and has been approved by the Health and Disability Ethics Committee.
Requirements
You may be eligible to participate in this trial if you meet the following criteria:
- Aged 18 – 60 years inclusive.
- In good health
- BMI (body mass index) between 18 and 32 kg/m2
- Not currently taking regular medicine (with exceptions)
- Women of childbearing potential must agree to use a highly effective method of contraception, along with a barrier form of contraception.
- Partners of women of childbearing potential must agree to use a highly effective method of contraception, along with a barrier form of contraception.
- No history of cancer within the last 5 years (with exceptions).
- Willing to refrain from coffee, tea, soft drinks, energy drinks and chocolate while on the study
- Limited tattooing on your body (less than 25% of body).
What is Involved?
Study Visits: 4-night stay + 1 follow-up phone call
Reimbursement: Up to $2,500 before tax